Targeting chromatin remodeling to prevent cardiovascular disease in diabetes

Current Pharmaceutical Biotechnology

Volumn 16, Issue 6, 2015, Pages 531-543

  Costantino, Sarah ^a   Paneni, Francesco ^a   Cosentino, Francesco ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Chromatin modifying agents; Diabetes; Metabolic memory epigenetics; Pharmacological reprogramming

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1; HISTONE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CPG ISLAND; DIABETES MELLITUS; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOTYPE ENVIRONMENT INTERACTION; GLYCEMIC CONTROL; HISTONE MODIFICATION; HUMAN; INSULIN SENSITIVITY; MORBIDITY; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; GENE THERAPY; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

CARDIOVASCULAR DISEASES; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS; GENETIC THERAPY; HISTONES; HUMANS; MODELS, CARDIOVASCULAR; MODELS, GENETIC; MOLECULAR TARGETED THERAPY;

EID: 84928946626     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920101606150407113644     Document Type: Article

References (138)

1. [I] Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur. Heart J., 2013, 34(31), 2436-2443.
2. Beckman, J.A.; Paneni, F.; Cosentino, F.; Creager, M.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur. Heart J., 2013, 34(31), 2444-2452.
3. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res., 2010, 107(9), 1058-1070.
4. Skyler, J.S.; Bergenstal, R.; Bonow, R.O.; Buse, J.; Deedwania, P.; Gale, E.A.; Howard, B.V.; Kirkman, M.S.; Kosiborod, M.; Reaven, P.; Sherwin, R.S.; American Diabetes, A.; American College of Cardiology, F.; American Heart, A. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol., 2009, 53(3), 298-304.
5. Boussageon, R.; Bejan-Angoulvant, T.; Saadatian-Elahi, M.; Lafont, S.; Bergeonneau, C.; Kassai, B.; Erpeldinger, S.; Wright, J.M.; Gueyffier, F.; Cornu, C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 2011, 343, d4169.
6. Paneni, F. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: Established knowledge and evidence gaps. Diab. Vasc. Dis. Res., 2014, 11(1), 5-10.
7. Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr.; Probstfield, J.L.; Simons-Morton, D.G.; Friedewald, W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2545-2559.
8. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Bompoint, S.; de Galan, B.E.; Joshi, R.; Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2560-2572.
9. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Reaven, P.D.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; Warren, S.R.; Goldman, S.; McCarren, M.; Vitek, M. E.; Henderson, W.G.; Huang, G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med., 2009, 360(2), 129-139.
10. Ceriello, A.; Ihnat, M.A.; Thorpe, J.E. Clinical review 2: The "metabolic memory": Is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab., 2009, 94(2), 410-415.
11. Cooper, M.E.; El-Osta, A. Epigenetics: Mechanisms and implications for diabetic complications. Circ. Res., 2010, 107(12), 1403-1413.
12. Paneni, F.; Costantino, S.; Cosentino, F. Insulin resistance, diabetes, and cardiovascular risk. Curr. Atheroscl. Rep., 2014, 16(7), 419.
13. Tabit, C.E.; Shenouda, S.M.; Holbrook, M.; Fetterman, J.L.; Kiani, S.; Frame, A.A.; Kluge, M.A.; Held, A.; Dohadwala, M.M.; Gokce, N.; Farb, M.G.; Rosenzweig, J.; Ruderman, N.; Vita, J.A.; Hamburg, N.M. Protein kinase C-beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation, 2013, 127(1), 86-95.
14. Pinton, P.; Rimessi, A.; Marchi, S.; Orsini, F.; Migliaccio, E.; Giorgio, M.; Contursi, C.; Minucci, S.; Mantovani, F.; Wieckowski, M.R.; Del Sal, G.; Pelicci, P.G.; Rizzuto, R. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science, 2007, 315(5812), 659-663.
15. Giorgio, M.; Migliaccio, E.; Orsini, F.; Paolucci, D.; Moroni, M.; Contursi, C.; Pelliccia, G.; Luzi, L.; Minucci, S.; Marcaccio, M.; Pinton, P.; Rizzuto, R.; Bernardi, P.; Paolucci, F.; Pelicci, P.G. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell, 2005, 122(2), 221-233.
16. Camici, G.G.; Schiavoni, M.; Francia, P.; Bachschmid, M.; Martin-Padura, I.; Hersberger, M.; Tanner, F.C.; Pelicci, P.; Volpe, M.; Anversa, P.; Luscher, T.F.; Cosentino, F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc. Natl. Acad. Sci. USA, 2007, 104(12), 5217-5222.
17. Pagnin, E.; Fadini, G.; de Toni, R.; Tiengo, A.; Calo, L.; Avogaro, A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J. Clin. Endocrinol. Metab., 2005, 90(2), 1130-1136.
18. Paneni, F.; Mocharla, P.; Akhmedov, A.; Costantino, S.; Osto, E.; Volpe, M.; Luscher, T.F.; Cosentino, F. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ. Res., 2012, 111(3), 278-289.
19. Baker, R.G.; Hayden, M.S.; Ghosh, S. NF-kappaB, inflammation, and metabolic disease. Cell Metab., 2011, 13(1), 11-22.
20. Hasegawa, Y.; Saito, T.; Ogihara, T.; Ishigaki, Y.; Yamada, T.; Imai, J.; Uno, K.; Gao, J.; Kaneko, K.; Shimosawa, T.; Asano, T.; Fujita, T.; Oka, Y.; Katagiri, H. Blockade of the nuclear factor-kappaB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation, 2012, 125(9), 1122-1133.
21. Paneni, F.; Costantino, S.; Cosentino, F. p66(Shc)-induced redox changes drive endothelial insulin resistance. Atherosclerosis, 2014, 236(2), 426-429.
22. Paneni, F.; Costantino, S.; Castello, L.; Battista, R.; Capretti, G.; Chiandotto, S.; D'Amario, D.; Scavone, G.; Villano, A.; Rustighi, A.; Crea, F.; Pitocco, D.; Lanza, G.; Volpe, M.; Del Sal, G.; Luscher, T.F.; Cosentino, F. Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. Eur. Heart J., 2014, 10.1093/eurheartj/ehu179.
23. Campos, E.I.; Reinberg, D. Histones: Annotating chromatin. Annu. Rev. Genet., 2009, 43, 559-599.
24. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997, 389(6648), 251-260.
25. Li, B.; Carey, M.; Workman, J.L. The role of chromatin during transcription. Cell, 2007, 128(4), 707-719.
26. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705.
27. Kim, G.H.; Ryan, J.J.; Archer, S.L. The role of redox signaling in epigenetics and cardiovascular disease. Antioxid. Redox Signal., 2013, 18(15), 1920-1936.
28. Paneni, F.; Costantino, S.; Volpe, M.; Luscher, T.F.; Cosentino, F. Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis, 2013, 230(2), 191-197.
29. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell, 2007, 128(4), 669-681.
30. Ramsahoye, B.H.; Biniszkiewicz, D.; Lyko, F.; Clark, V.; Bird, A.P.; Jaenisch, R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5237-5242.
31. Baccarelli, A.; Ghosh, S. Environmental exposures, epigenetics and cardiovascular disease. Curr. Opin. Clin. Nutr. Metab. Care, 2012, 15(4), 323-329.
32. Handy, D.E.; Castro, R.; Loscalzo, J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation, 2011, 123(19), 2145-2156.
33. Miranda, T.B.; Jones, P.A. DNA methylation: the nuts and bolts of repression. J. Cell. Physiol., 2007, 213(2), 384-390.
34. Matouk, C.C.; Marsden, P.A. Epigenetic regulation of vascular endothelial gene expression. Circ. Res., 2008, 102(8), 873-887.
35. Ling, C.; Groop, L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes, 2009, 58(12), 2718-2725.
36. Wu, S.C.; Zhang, Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell. Biol., 2010, 11(9), 607-620.
37. Franchini, D.M.; Schmitz, K.M.; Petersen-Mahrt, S.K. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu. Rev. Genet., 2012, 46, 419-441.
38. Kohli, R.M.; Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature, 2013, 502(7472), 472-479.
39. Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol., 2005, 6(11), 838-849.
40. Jenuwein, T.; Allis, C.D. Translating the histone code. Science, 2001, 293(5532), 1074-1080.
41. Shahbazian, M.D.; Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem., 2007, 76, 75-100.
42. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 2009, 10(1), 32-42.
43. Lavebratt, C.; Almgren, M.; Ekstrom, T.J. Epigenetic regulation in obesity. Int. J. Obes., 2012, 36(6), 757-765.
44. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784.
45. Thiagalingam, S.; Cheng, K.H.; Lee, H.J.; Mineva, N.; Thiagalingam, A.; Ponte, J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci., 2003, 983, 84-100.
46. Bannister, A.J.; Kouzarides, T. Reversing histone methylation. Nature, 2005, 436(7054), 1103-1106.
47. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J.R.; Cole, P.A.; Casero, R.A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004, 119(7), 941-953.
48. Metzger, E.; Wissmann, M.; Yin, N.; Muller, J.M.; Schneider, R.; Peters, A.H.; Gunther, T.; Buettner, R.; Schule, R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature, 2005, 437(7057), 436-439.
49. Villeneuve, L.M.; Natarajan, R. The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol., 2010, 299(1), F14-25.
50. Whetstine, J.R.; Nottke, A.; Lan, F.; Huarte, M.; Smolikov, S.; Chen, Z.; Spooner, E.; Li, E.; Zhang, G.; Colaiacovo, M.; Shi, Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell, 2006, 125(3), 467-481.
51. Tateishi, K.; Okada, Y.; Kallin, E. M.; Zhang, Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature, 2009, 458(7239), 757-761.
52. Schubeler, D.; Lorincz, M.C.; Cimbora, D.M.; Telling, A.; Feng, Y.Q.; Bouhassira, E.E.; Groudine, M. Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol. Cell. Biol., 2000, 20(24), 9103-9112.
53. Cedar, H.; Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet., 2009, 10(5), 295-304.
54. Pinney, S.E.; Simmons, R.A. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol. Metab., 2010, 21(4), 223-229.
55. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell, 2007, 128(4), 683-692.
56. Shirodkar, A.V.; Marsden, P.A. Epigenetics in cardiovascular disease. Curr. Opin. Cardiol., 2011, 26(3), 209-215.
57. Lund, G.; Andersson, L.; Lauria, M.; Lindholm, M.; Fraga, M.F.; Villar-Garea, A.; Ballestar, E.; Esteller, M.; Zaina, S. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J. Biol. Chem., 2004, 279(28), 29147-29154.
58. Puigserver, P.; Spiegelman, B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev., 2003, 24(1), 78-90.
59. Das, S.K.; Chakrabarti, R. Role of PPAR in cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov., 2006, 1(2), 193-209.
60. Ling, C.; Del Guerra, S.; Lupi, R.; Ronn, T.; Granhall, C.; Luthman, H.; Masiello, P.; Marchetti, P.; Groop, L.; Del Prato, S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia, 2008, 51(4), 615-622.
61. Fish, J.E.; Yan, M.S.; Matouk, C.C.; St Bernard, R.; Ho, J.J.; Gavryushova, A.; Srivastava, D.; Marsden, P.A. Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histones. J. Biol. Chem., 2010, 285(2), 810-826.
62. Chen, H.; Yan, Y.; Davidson, T.L.; Shinkai, Y.; Costa, M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res., 2006, 66(18), 9009-9016.
63. Mattagajasingh, I.; Kim, C.S.; Naqvi, A.; Yamamori, T.; Hoffman, T.A.; Jung, S.B.; DeRicco, J.; Kasuno, K.; Irani, K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 2007, 104(37), 14855-14860.
64. Chan, G.C.; Fish, J.E.; Mawji, I.A.; Leung, D.D.; Rachlis, A.C.; Marsden, P.A. Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J. Immunol., 2005, 175(6), 3846-3861.
65. Reddy, M.A.; Natarajan, R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc. Res., 2011, 90(3), 421-429.
66. O'Hagan, H.M.; Wang, W.; Sen, S.; Destefano Shields, C.; Lee, S.S.; Zhang, Y.W.; Clements, E.G.; Cai, Y.; Van Neste, L.; Easwaran, H.; Casero, R.A.; Sears, C.L.; Baylin, S.B. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell, 2011, 20(5), 606-619.
67. Zaina, S.; Lindholm, M.W.; Lund, G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J. Nutr., 2005, 135(1), 5-8.
68. Milagro, F.I.; Campion, J.; Garcia-Diaz, D.F.; Goyenechea, E.; Paternain, L.; Martinez, J.A. High fat diet-induced obesity modifies the methylation pattern of leptin promoter in rats. J. Physiol. Biochem., 2009, 65(1), 1-9.
69. Laukkanen, M.O.; Mannermaa, S.; Hiltunen, M.O.; Aittomaki, S.; Airenne, K.; Janne, J.; Yla-Herttuala, S. Local hypomethylation in atherosclerosis found in rabbit ec-SOD gene. Arterioscler. Thromb. Vasc. Biol., 1999, 19(9), 2171-2178.
70. Miao, F.; Wu, X.; Zhang, L.; Yuan, Y.C.; Riggs, A.D.; Natarajan, R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J. Biol. Chem., 2007, 282(18), 13854-13863.
71. Miao, F.; Smith, D.D.; Zhang, L.; Min, A.; Feng, W.; Natarajan, R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: An epigenetic study in diabetes. Diabetes, 2008, 57(12), 3189-3198.
72. Li, S.L.; Reddy, M.A.; Cai, Q.; Meng, L.; Yuan, H.; Lanting, L.; Natarajan, R. Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes, 2006, 55(9), 2611-2619.
73. Yerneni, K.K.; Bai, W.; Khan, B.V.; Medford, R.M.; Natarajan, R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes, 1999, 48(4), 855-864.
74. Brasacchio, D.; Okabe, J.; Tikellis, C.; Balcerczyk, A.; George, P.; Baker, E.K.; Calkin, A.C.; Brownlee, M.; Cooper, M.E.; El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes, 2009, 58(5), 1229-1236.
75. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P.L.; Roeder, R.G.; Cooper, M.E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med., 2008, 205(10), 2409-2417.
76. Keating, S.T.; El-Osta, A. Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics, 2013, 8(4), 361-372.
77. Li, Y.; Reddy, M.A.; Miao, F.; Shanmugam, N.; Yee, J.K.; Hawkins, D.; Ren, B.; Natarajan, R. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J. Biol. Chem., 2008, 283(39), 26771-26781.
78. Paneni, F.; Costantino, S.; Battista, R.; Castello, L.; Capretti, G.; Chiandotto, S.; Scavone, G.; Villano, A.; Pitocco, D.; Lanza, G.; Volpe, M.; Luscher, T.F.; Cosentino, F. Adverse Epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes. Circ. Cardiovasc. Genet., 2014, 8(1), 150-158.
79. Villeneuve, L.M.; Reddy, M.A.; Lanting, L.L.; Wang, M.; Meng, L.; Natarajan, R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. USA, 2008, 105(26), 9047-9052.
80. Miao, F.; Gonzalo, I.G.; Lanting, L.; Natarajan, R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem., 2004, 279(17), 18091-18097.
81. Orimo, M.; Minamino, T.; Miyauchi, H.; Tateno, K.; Okada, S.; Moriya, J.; Komuro, I. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler. Thromb. Vasc. Biol., 2009, 29(6), 889-894.
82. Paneni, F.; Volpe, M.; Luscher, T.F.; Cosentino, F. SIRT1, p66Shc, and Set7/9 in vascular hyperglycemic memory: Bringing all the strands together. Diabetes, 2013, 62(6), 1800-1807.
83. Paneni, F.; Costantino, S.; Cosentino, F. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovasc. Diagn. Ther., 2014, 4(4), 324-332.
84. Napoli, C.; Crudele, V.; Soricelli, A.; Al-Omran, M.; Vitale, N.; Infante, T.; Mancini, F.P. Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms? Circulation, 2012, 125(19), 2363-2373.
85. Wang, J.; Wu, Z.; Li, D.; Li, N.; Dindot, S.V.; Satterfield, M.C.; Bazer, F.W.; Wu, G. Nutrition, epigenetics, and metabolic syndrome. Antioxid. Redox Signal., 2012, 17(2), 282-301.
86. Li, C.C.; Cropley, J.E.; Cowley, M.J.; Preiss, T.; Martin, D.I.; Suter, C.M. A sustained dietary change increases epigenetic variation in isogenic mice. PLoS Genet., 2011, 7(4), e1001380.
87. Li, J.; Huang, J.; Li, J.S.; Chen, H.; Huang, K.; Zheng, L. Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J. Hepatol., 2012, 56(4), 900-907.
88. Dunn, G.A.; Bale, T.L. Maternal high-fat diet promotes body length increases and insulin insensitivity in second-generation mice. Endocrinology, 2009, 150(11), 4999-5009.
89. Olsen, A.S.; Sarras, M.P., Jr.; Leontovich, A.; Intine, R.V. Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes, 2012, 61(2), 485-491.
90. Pettitt, D.J.; Baird, H.R.; Aleck, K.A.; Bennett, P.H.; Knowler, W.C. Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N. Engl. J. Med., 1983, 308(5), 242-245.
91. Lehnen, H.; Zechner, U.; Haaf, T. Epigenetics of gestational diabetes mellitus and offspring health: the time for action is in early stages of life. Mol. Hum. Reprod., 2013, 19(7), 415-422.
92. Roseboom, T.J.; Painter, R.C.; van Abeelen, A.F.; Veenendaal, M.V.; de Rooij, S.R. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas, 2011, 70(2), 141-145.
93. Heijmans, B.T.; Tobi, E.W.; Lumey, L.H.; Slagboom, P.E. The epigenome: archive of the prenatal environment. Epigenetics, 2009, 4(8), 526-531.
94. Brown, A.S.; Susser, E.S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr. Bull., 2008, 34(6), 1054-1063.
95. Kim, C.S.; Kim, Y.R.; Naqvi, A.; Kumar, S.; Hoffman, T.A.; Jung, S.B.; Kumar, A.; Jeon, B. H.; McNamara, D.M.; Irani, K. Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovasc. Res., 2011, 92(3), 466-475.
96. Krishna, S.M.; Dear, A.; Craig, J.M.; Norman, P.E.; Golledge, J. The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis, 2013, 228(2), 295-305.
97. Yi, P.; Melnyk, S.; Pogribna, M.; Pogribny, I.P.; Hine, R.J.; James, S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem., 2000, 275(38), 29318-29323.
98. Ly, A.; Hoyt, L.; Crowell, J.; Kim, Y.I. Folate and DNA methylation. Antioxid. Redox Signal., 2012, 17(2), 302-326.
99. Jacob, R.A.; Gretz, D.M.; Taylor, P.C.; James, S.J.; Pogribny, I.P.; Miller, B.J.; Henning, S. M.; Swendseid, M.E. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J. Nutr., 1998, 128(7), 1204-1212.
100. Advani, A.; Huang, Q.; Thai, K.; Advani, S.L.; White, K.E.; Kelly, D.J.; Yuen, D.A.; Connelly, K.A.; Marsden, P.A.; Gilbert, R.E. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am. J. Pathol., 2011, 178(5), 2205-2214.
101. Wang, D.; Zhao, M.; Chen, G.; Cheng, X.; Han, X.; Lin, S.; Zhang, X.; Yu, X. The histone deacetylase inhibitor vorinostat prevents TNFalpha-induced necroptosis by regulating multiple signaling pathways. Apoptosis, 2013, 18(11), 1348-1362.
102. Xie, M.; Kong, Y.; Tan, W.; May, H.; Battiprolu, P.K.; Pedrozo, Z.; Wang, Z.V.; Morales, C.; Luo, X.; Cho, G.; Jiang, N.; Jessen, M.E.; Warner, J.J.; Lavandero, S.; Gillette, T.G.; Turer, A.T.; Hill, J.A. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation, 2014, 129(10), 1139-1151.
103. Paneni, F.; Gregori, M.; Tocci, G.; Palano, F.; Ciavarella, G.M.; Pignatelli, G.; Marra, A.; Sciarretta, S.; Ferrucci, A.; Volpe, M. Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertens. Res., 2013, 36(1), 36-42.
104. Gallo, P.; Latronico, M.V.; Gallo, P.; Grimaldi, S.; Borgia, F.; Todaro, M.; Jones, P.; Gallinari, P.; De Francesco, R.; Ciliberto, G.; Steinkuhler, C.; Esposito, G.; Condorelli, G. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res., 2008, 80(3), 416-424.
105. Noh, H.; Oh, E.Y.; Seo, J.Y.; Yu, M.R.; Kim, Y.O.; Ha, H.; Lee, H.B. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol., 2009, 297(3), F729-739.
106. Zhang, L.; Qin, X.; Zhao, Y.; Fast, L.; Zhuang, S.; Liu, P.; Cheng, G.; Zhao, T.C. Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J. Pharmacol. Exp. Ther., 2012, 341(1), 285-293.
107. Zhao, T.C.; Cheng, G.; Zhang, L.X.; Tseng, Y.T.; Padbury, J.F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc. Res., 2007, 76(3), 473-481.
108. Hu, X.; Zhang, K.; Xu, C.; Chen, Z.; Jiang, H. Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion. Exp. Ther. Med., 2014, 8(1), 229-232.
109. Mathew, O.P.; Ranganna, K.; Milton, S.G. Involvement of the Antioxidant effect and anti-inflammatory response in butyrate-inhibited vascular smooth muscle cell proliferation. Pharmaceuticals (Basel), 2014, 7(11), 1008-1027.
110. Cardinale, J.P.; Sriramula, S.; Pariaut, R.; Guggilam, A.; Mariappan, N.; Elks, C.M.; Francis, J. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension, 2010, 56(3), 437-444.
111. Fessler, E.B.; Chibane, F.L.; Wang, Z.; Chuang, D.M. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Curr. Pharm. Des., 2013, 19(28), 5105-5120.
112. Suda, S.; Katsura, K.; Kanamaru, T.; Saito, M.; Katayama, Y. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur. J. Pharmacol., 2013, 707(1-3), 26-31.
113. de Ligt, M.; Timmers, S.; Schrauwen, P. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochim. Biophys. Acta, 2014, 10.1016/j.bbadis.2014.11.012.
114. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; Hubbard, B.P.; Varela, A.T.; Davis, J. G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A.P.; Coppari, R.; Palmeira, C.M.; de Cabo, R.; Baur, J. A.; Sinclair, D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15(5), 675-690.
115. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127(6), 1109-1122.
116. Zabolotny, J.M.; Kim, Y.B. Silencing insulin resistance through SIRT1. Cell Metab., 2007, 6(4), 247-249.
117. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; Moonen-Kornips, E.; Hesselink, M.K.; Kunz, I.; Schrauwen-Hinderling, V.B.; Blaak, E.E.; Auwerx, J.; Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab., 2011, 14(5), 612-622.
118. Lekakis, J.; Rallidis, L.S.; Andreadou, I.; Vamvakou, G.; Kazantzoglou, G.; Magiatis, P.; Skaltsounis, A.L.; Kremastinos, D.T. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil., 2005, 12(6), 596-600.
119. Wong, R.H.; Howe, P.R.; Buckley, J.D.; Coates, A.M.; Kunz, I.; Berry, N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis., 2011, 21(11), 851-856.
120. Sulaiman, M.; Matta, M.J.; Sunderesan, N.R.; Gupta, M.P.; Periasamy, M.; Gupta, M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(3), H833-843.
121. Zhang, H.; Morgan, B.; Potter, B.J.; Ma, L.; Dellsperger, K.C.; Ungvari, Z.; Zhang, C. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: In vivo demonstration with magnetic resonance imaging. Am. J. Physiol. Heart Circ. Physiol., 2010, 299(4), H985-994.
122. Raj, P.; Louis, X.L.; Thandapilly, S.J.; Movahed, A.; Zieroth, S.; Netticadan, T. Potential of resveratrol in the treatment of heart failure. Life Sci., 2014, 95(2), 63-71.
123. Poulsen, M.M.; Vestergaard, P.F.; Clasen, B.F.; Radko, Y.; Christensen, L.P.; Stodkilde-Jorgensen, H.; Moller, N.; Jessen, N.; Pedersen, S.B.; Jorgensen, J.O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2013, 62(4), 1186-1195.
124. Zheng, Z.; Chen, H.; Li, J.; Li, T.; Zheng, B.; Zheng, Y.; Jin, H.; He, Y.; Gu, Q.; Xu, X. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes, 2012, 61(1), 217-228.
125. Arunachalam, G.; Samuel, S.M.; Marei, I.; Ding, H.; Triggle, C.R. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br. J. Pharmacol., 2014, 171(2), 523-535.
126. El Messaoudi, S.; Rongen, G.A.; de Boer, R.A.; Riksen, N.P. The cardioprotective effects of metformin. Curr. Opin. Lipidol., 2011, 22(6), 445-453.
127. Lexis, C.P.; van der Horst, I.C.; Lipsic, E.; Wieringa, W.G.; de Boer, R.A.; van den Heuvel, A.F.; van der Werf, H.W.; Schurer, R.A.; Pundziute, G.; Tan, E.S.; Nieuwland, W.; Willemsen, H.M.; Dorhout, B.; Molmans, B.H.; vanderHorstSchrivers, A.N.; Wolffenbuttel, B.H.; ter Horst, G.J.; van Rossum, A.C.; Tijssen, J.G.; Hillege, H.L.; de Smet, B.J.; van der Harst, P.; van Veldhuisen, D.J.; Investigators, G.I. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: The GIPS-III randomized clinical trial. JAMA, 2014, 311(15), 1526-1535.
128. Kim, S.J.; Nian, C.; McIntosh, C.H. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J. Biol. Chem., 2009, 284(19), 12896-12904.
129. Bastien-Dionne, P.O.; Valenti, L.; Kon, N.; Gu, W.; Buteau, J. Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic beta-cell mass expansion. Diabetes, 2011, 60(12), 3217-3222.
130. Plutzky, J. The PPAR-RXR transcriptional complex in the vasculature: Energy in the balance. Circ. Res., 2011, 108(8), 1002-1016.
131. Srivastava, G.; Mehta, J.L. Currying the heart: curcumin and cardioprotection. J. Cardiovasc. Pharmacol. Ther., 2009, 14(1), 22-27.
132. Sunagawa, Y.; Morimoto, T.; Wada, H.; Takaya, T.; Katanasaka, Y.; Kawamura, T.; Yanagi, S.; Marui, A.; Sakata, R.; Shimatsu, A.; Kimura, T.; Kakeya, H.; Fujita, M.; Hasegawa, K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ. J., 2011, 75(9), 2151-2159.
133. Coban, D.; Milenkovic, D.; Chanet, A.; Khallou-Laschet, J.; Sabbe, L.; Palagani, A.; Vanden Berghe, W.; Mazur, A.; Morand, C. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol. Nutr. Food Res., 2012, 56(8), 1270-1281.
134. Maradana, M.R.; Thomas, R.; O'Sullivan, B.J. Targeted delivery of curcumin for treating type 2 diabetes. Mol. Nutr. Food Res., 2013, 57(9), 1550-1556.
135. Ordovas, J.M.; Smith, C.E. Epigenetics and cardiovascular disease. Nat. Rev. Cardiol., 2010, 7(9), 510-519.
136. Shin, I.S.; Kim, J.M.; Kim, K.L.; Jang, S.Y.; Jeon, E.S.; Choi, S.H.; Kim, D.K.; Suh, W.; Kim, Y.W. Early growth response factor-1 is associated with intraluminal thrombus formation in human abdominal aortic aneurysm. J. Am. Coll. Cardiol., 2009, 53(9), 792-799.
137. Abdel-Malak, N.A.; Mofarrahi, M.; Mayaki, D.; Khachigian, L.M.; Hussain, S.N. Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. Arterioscler. Thromb. Vasc. Biol., 2009, 29(2), 209-216.
138. Wang, B.; Chen, J.; Santiago, F.S.; Janes, M.; Kavurma, M.M.; Chong, B.H.; Pimanda, J.E.; Khachigian, L.M. Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. Arterioscler. Thromb. Vasc. Biol., 2010, 30(3), 536-545.